Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Condition(s):Heart FailureLast Updated:November 7, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Heart FailureLast Updated:November 7, 2023Completed
Condition(s):Atrial FibrillationLast Updated:November 7, 2023Completed
Condition(s):HealthyLast Updated:August 1, 2019Completed
Condition(s):Deep Vein Thrombosis; Venous ThromboembolismLast Updated:January 18, 2020Unknown status
Condition(s):ThrombosisLast Updated:April 16, 2019Completed
Condition(s):Therapeutic EquivalencyLast Updated:April 22, 2015Completed
Condition(s):Peripheral Artery DiseaseLast Updated:December 8, 2020Completed
Condition(s):Thromboses, Deep Vein; Surgery–ComplicationsLast Updated:October 17, 2017Unknown status
Condition(s):Atrial FibrillationLast Updated:June 28, 2023Completed
Condition(s):Atrial FibrillationLast Updated:July 25, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.